Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
11/17/2017 11/20/2017 11/21/2017 11/22/2017 11/24/2017 Date
93.61(c) 93.6(c) 94.68(c) 94.47(c) 94.72(c) Last
3 386 427 4 352 234 4 346 213 2 560 662 1 932 938 Volume
-0.91% -0.01% +1.15% -0.22% +0.26% Change
More quotes
Financials ($)
Sales 2017 28 001 M
EBIT 2017 11 957 M
Net income 2017 7 316 M
Debt 2017 26 790 M
Yield 2017 2,75%
Sales 2018 30 977 M
EBIT 2018 13 846 M
Net income 2018 9 047 M
Debt 2018 22 995 M
Yield 2018 3,05%
P/E ratio 2017 20,26
P/E ratio 2018 16,24
EV / Sales2017 6,35x
EV / Sales2018 5,62x
Capitalization 151 B
More Financials
Company
AbbVie, Inc. is a research-based biopharmaceutical company.It engages in the discovery, development, manufacture and sale of a broad line of proprietary pharmaceutical products.The company focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and... 
Sector
Pharmaceuticals
Calendar
11/29 | 02:00pmPresentation
More about the company
Surperformance© ratings of AbbVie
Trading Rating : Investor Rating :
More Ratings
Latest news on ABBVIE
11/23 ABBVIE : Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at ..
11/23 ABBVIE : Galapagos initiates Phase 1 study with novel CF corrector GLPG3221
11/22 ENANTA PHARMACEUTICALS : Reports Financial Results for its Fourth Quarter and Ye..
11/21 ABBVIE : Investigators at AbbVie Describe Findings in Molecular Biology (Bin1 di..
11/21 ABBVIE : Reports Summarize Antihyperlipidemic Agents Findings from AbbVie (Extra..
11/21 ABBVIE : Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at ..
11/21 Brexit gets real for drugmakers as regulator moves to Amsterdam
11/17 ABBVIE : to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Confer..
11/16 ABBVIE : Reports Outline Organic Research Study Results from AbbVie (Use of a Po..
11/16 ABBVIE : concludes training program for Saudi pharmacists
More news
Sector news : Specialty & Advanced Pharmaceuticals
11/24DJSHIRE PLC SHIRE PLC : Block Listing Interim Review -2-
11/24DJSHIRE PLC SHIRE PLC : Block Listing Interim Review
11/24DJBAYER : Amikacin Inhale Fails to Meet Objectives in Phase 3 Trial
11/23 German chemicals companies should review British ops - trade body
11/23DJGLAXOSMITHKLINE : Files Additional Trelegy Ellipta Application to FDA
More sector news : Specialty & Advanced Pharmaceuticals
4-Traders Strategies on ABBVIE 
ABBVIE  - 2015
A likely recovery
BUY
More Strategies
News from SeekingAlpha
11/23 Tracking Larry Robbins' Glenview Capital Management Portfolio - Q3 2017 Updat..
11/22 GILEAD : Buying New Growth
11/22 YOUR DAILY PHARMA SCOOP : Teva Valuation, DelMar Lead Candidate, Galapagos Comme..
11/22 Mystery Stocks Revealed In My 88 Stock Portfolio Along With 2018 Income Estim..
11/22 Trading Quality Stocks And Short Term Rates Higher Update
Chart ABBVIE
Duration : Period :
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 97,9 $
Spread / Average Target 3,4%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE50.86%150 993
MERCK KGAA-10.09%13 750
KYOWA HAKKO KIRIN CO LTD27.81%10 749
JAZZ PHARMACEUTICALS PLC26.61%8 276
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD39.68%5 855
CONVATEC GROUP-16.42%5 149